Neurocrine Biosciences Inc (NBIX) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
Total Assets Chart for Neurocrine Biosciences Inc
Neurocrine Biosciences Inc (NBIX) total assets for FY2025 were USD 4.6B, a 24.5% change from FY2024. Neurocrine Biosciences Inc's total assets grew from USD 78.0M in 1996 to USD 4.6B in 2025 (5837.8% over 29 years). Total assets compound annual growth rate: 5-year CAGR of 21.7%, 10-year CAGR of 25.6%, 20-year CAGR of 12.0%.
Total Assets (US Dollars)
R&D as % of Revenue
Key Stats
- Market Cap
- $14.79B
- Implied Share Price
- $145.51
- Enterprise Value
- $14.42B
- Revenue (TTM)
- $3.37B
- EBITDA
- $913.30M
- Profit Margin
- 20.91%
- Trailing P/E
- 21.15
- Forward P/E
- 14.12
- Price/Book (MRQ)
- 3.90
- Price/Sales (TTM)
- 4.38
- EV/EBITDA
- 15.65
- EV/Revenue
- 4.28
- Dividend Yield
- —
- Book Value
- $36.35
- Free Cash Flow (FY2025)
- $748.70M
- Free Cash Flow Yield
- 5.06%
Snapshot as of 6th October 2026 — not point-in-time controlled, may lag the live market by a few days.